Open AccessExpert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors
Author(s) -
Imai Mitsuho,
Nakamura Yoshiaki,
Sunami Kuniko,
Kage Hidenori,
Komine Keigo,
Koyama Takafumi,
Amano Toraji,
Ennishi Daisuke,
Kanai Masashi,
Kenmotsu Hirotsugu,
Maeda Takahiro,
Morita Sachi,
Sakai Daisuke,
Bando Hideaki,
Makiyama Akitaka,
Suzuki Tatsuya,
Hirata Makoto,
Kohsaka Shinji,
Tsuchihara Katsuya,
Naito Yoichi,
Yoshino Takayuki
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15504
Subject(s) - circulating tumor dna , precision medicine , profiling (computer programming) , turnaround time , medicine , personalized medicine , computational biology , false positive paradox , bioinformatics , oncology , cancer , biology , pathology , computer science , machine learning , operating system
Comprehensive genomic profiling is increasingly used to facilitate precision oncology based on molecular stratification. In addition to conventional tissue comprehensive genomic profiling, comprehensive genomic profiling of circulating tumor DNA has become widely utilized in cancer care owing on its advantages, including less invasiveness, rapid turnaround time, and capturing heterogeneity. However, circulating tumor DNA comprehensive genomic profiling has some limitations, mainly false negatives due to low levels of plasma circulating tumor deoxyribonucleic acid and false positives caused by clonal hematopoiesis. Nevertheless, no guidelines and recommendations fully address these issues. Here, an expert panel committee involving representatives from 12 Designated Core Hospitals for Cancer Genomic Medicine in Japan was organized to develop expert consensus recommendations for the use of circulating tumor deoxyribonucleic acid‐based comprehensive genomic profiling. The aim was to generate guidelines for clinicians and allied healthcare professionals on the optimal use of the circulating tumor DNA assays in advanced solid tumors and to aid the design of future clinical trials that utilize and develop circulating tumor DNA assays to refine precision oncology. Fourteen clinical questions regarding circulating tumor deoxyribonucleic acid comprehensive genomic profiling including the timing of testing and considerations for interpreting results were established by searching and curating associated literatures, and corresponding recommendations were prepared based on the literature for each clinical question. Final consensus recommendations were developed by voting to determine the level of each recommendation by the Committee members.